Advertisement
LIVN vs ZBH
Which Stock Would AI Choose? LivaNova (LIVN) vs. Zimmer Biomet (ZBH) Stock Comparison
Key Takeaways
- LivaNova (LIVN) has delivered stronger year-to-date (YTD) performance at +4.34% compared to Zimmer Biomet's (ZBH) +1.77%.
- LIVN, with a market cap of $3.5 billion, offers higher growth potential in neuromodulation amid recent positive clinical data on sleep apnea therapy.
- ZBH's larger $17.7 billion market cap provides stability in orthopedics, supported by robotics advancements like the ROSA system.
- Both stocks operate in the competitive medical technology sector, but LIVN shows superior one-year returns around 71% versus ZBH's decline.
- Recent earnings beats for both, though ZBH issued a cautious 2026 outlook.
Introduction
LivaNova (LIVN) and Zimmer Biomet (ZBH) represent key players in the medical technology sector, focusing on specialized devices for cardiovascular, neuromodulation, and orthopedic reconstructive procedures. This comparison analyzes their recent market performance, business drivers, and relative positioning amid evolving healthcare demands. Investors tracking medtech stocks for growth opportunities or stability in a volatile market, as well as traders eyeing short-term momentum, will find value in understanding contrasts in scale, innovation pipelines, and sentiment shifts. With both companies reporting solid Q4 2025 results earlier this year, attention turns to ongoing catalysts and sector trends.
LIVN Overview and Recent Performance
LivaNova PLC (LIVN) is a medical technology firm specializing in cardiopulmonary products like heart-lung machines and oxygenators, alongside neuromodulation therapies such as the VNS Therapy system for drug-resistant epilepsy and depression. Recent market activity has seen LIVN stock trading around $64, with YTD gains of 4.34% and robust one-year returns near 71%. In recent weeks, positive sentiment stemmed from the publication of 12-month results from the OSPREY clinical study for obstructive sleep apnea therapy in Annals of Internal Medicine, highlighting potential expansion in neuromodulation. Q4 2025 earnings beat estimates, with mid-to-high single-digit growth guidance for 2026, bolstering confidence despite broader market pressures.
ZBH Overview and Recent Performance
Zimmer Biomet Holdings, Inc. (ZBH) designs and markets orthopedic reconstructive products, including knee and hip implants, sports medicine solutions, and robotic systems like ROSA for precise surgeries. The stock has hovered near $91 in recent trading, posting YTD returns of 1.77% amid softer one-year performance. Recent developments include focus on robotics integration and share buybacks, with analysts noting mixed views ahead of Q1 2026 earnings. Q4 2025 results exceeded expectations on sales growth, particularly in knees (6.9% constant currency), though 2026 guidance adopted a measured tone due to procedural volume uncertainties. Dividend declarations further support investor stability.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 performers from over 351 AI trading bots that analyze and trade thousands of tickers across stocks, ETFs, and crypto. Selected for current market conditions like volatility in semiconductors and gold miners, these bots employ diverse strategies—trend following, multi-ticker portfolios, and volatility plays using 2x/3x leveraged ETFs. Performance stats impress: annualized returns range from +15% to +167%, win rates from 48% to 88%, profit factors up to 11.7, and drawdown ratios exceeding 20 in top cases. Signal, Virtual, and Brokerage Agents cater to various risk levels and timeframes from minutes to months. Traders can explore these to align with personalized styles in today's dynamic environment.
Head-to-Head Comparison
LIVN and ZBH both thrive in medtech but diverge in focus: LIVN's cardiopulmonary and neuromodulation targets niche therapies like vagus nerve stimulation (VNS), while ZBH dominates orthopedic reconstruction with knees, hips, and robotics. Growth drivers contrast too—LIVN leverages sleep apnea expansions versus ZBH's ROSA robotics and ZBEdge platform for data-driven surgeries. Recent momentum favors LIVN with stronger YTD and longer-term gains, though ZBH's scale mitigates risks from procedural slowdowns. LIVN carries higher volatility as a smaller cap, while ZBH benefits from diversified exposure. Market sentiment tilts toward LIVN buys amid clinical wins, contrasting ZBH's hold ratings.
Tickeron AI Verdict
Tickeron's AI models currently favor LIVN over ZBH, driven by superior trend consistency, YTD outperformance, and catalysts like the recent OSPREY study publication. LIVN's smaller size positions it for higher relative upside in neuromodulation growth, while ZBH offers stability but lags in momentum. This assessment reflects probabilistic signals from recent data, subject to market shifts and earnings outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LIVN is a Hold and ZBH is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LIVN’s FA Score shows that 0 FA rating(s) are green whileZBH’s FA Score has 1 green FA rating(s).
- LIVN’s FA Score: 0 green, 5 red.
- ZBH’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LIVN’s TA Score shows that 3 TA indicator(s) are bullish while ZBH’s TA Score has 4 bullish TA indicator(s).
- LIVN’s TA Score: 3 bullish, 5 bearish.
- ZBH’s TA Score: 4 bullish, 5 bearish.
Price Growth
LIVN (@Medical/Nursing Services) experienced а -1.25% price change this week, while ZBH (@Medical/Nursing Services) price change was -1.33% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.03%. For the same industry, the average monthly price growth was -3.68%, and the average quarterly price growth was -16.13%.
Reported Earning Dates
LIVN is expected to report earnings on Jul 29, 2026.
ZBH is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.03% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| LIVN | ZBH | LIVN / ZBH | |
| Capitalization | 4.32B | 16.8B | 26% |
| EBITDA | 225M | 2.31B | 10% |
| Gain YTD | 27.905 | -2.884 | -967% |
| P/E Ratio | 40.15 | 22.56 | 178% |
| Revenue | 1.43B | 8.41B | 17% |
| Total Cash | 540M | 424M | 127% |
| Total Debt | 343M | 7.47B | 5% |
LIVN | ZBH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 74 | 83 | |
PRICE GROWTH RATING 1..100 | 41 | 55 | |
P/E GROWTH RATING 1..100 | 40 | 40 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZBH's Valuation (9) in the Medical Specialties industry is somewhat better than the same rating for LIVN (71). This means that ZBH’s stock grew somewhat faster than LIVN’s over the last 12 months.
ZBH's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as LIVN (100). This means that ZBH’s stock grew similarly to LIVN’s over the last 12 months.
LIVN's SMR Rating (74) in the Medical Specialties industry is in the same range as ZBH (83). This means that LIVN’s stock grew similarly to ZBH’s over the last 12 months.
LIVN's Price Growth Rating (41) in the Medical Specialties industry is in the same range as ZBH (55). This means that LIVN’s stock grew similarly to ZBH’s over the last 12 months.
LIVN's P/E Growth Rating (40) in the Medical Specialties industry is in the same range as ZBH (40). This means that LIVN’s stock grew similarly to ZBH’s over the last 12 months.
| LIVN | ZBH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 65% | 2 days ago 68% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 67% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 67% |
| MACD ODDS (%) | 2 days ago 80% | N/A |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 54% |
| Advances ODDS (%) | 13 days ago 68% | 19 days ago 64% |
| Declines ODDS (%) | 7 days ago 74% | 13 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 73% | 2 days ago 58% |
| Aroon ODDS (%) | 2 days ago 60% | 2 days ago 54% |
Advertisement
ZBH and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZBH has been loosely correlated with KIDS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBH jumps, then KIDS could also see price increases.
| Ticker / NAME | Correlation To ZBH | 1D Price Change % | ||
|---|---|---|---|---|
| ZBH | 100% | -1.00% | ||
| KIDS - ZBH | 45% Loosely correlated | -3.66% | ||
| ENOV - ZBH | 45% Loosely correlated | -3.05% | ||
| CNMD - ZBH | 44% Loosely correlated | -0.12% | ||
| SYK - ZBH | 44% Loosely correlated | -1.01% | ||
| LIVN - ZBH | 44% Loosely correlated | +0.25% | ||
More | ||||